Northwoods NETS

URGENT ACTION NEEDED: Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 (H.R. 3772)

Action Requested by November 1, 2019 On October 18, 2019, an opinion piece that NorCal CarciNET Community’s Josh Mailman opinion article (“CMS policy shouldn’t penalize those with rare disease”) was published by The Hill,  The opinion piece highlighted the challenges with the current method that Medicare/CMS use to pay for radiopharmaceuticals. This webpage provides more information on how this will impact NET patients and providers along with a  tool for those that are

M. Sue O'Dorisio

University of Iowa Holden Comprehensive Cancer Center is the first U.S. cancer center to be designated a Neuroendocrine Tumor Center of Excellence by the European Neuroendocrine Tumor Society (ENETS). In making the award to the Iowa team in early March, ENETS listed its criteria for the distinction, including The Holden team’s advanced interdisciplinary approach for diagnosing neuroendocrine tumor (NET) patients The quality and breadth of the team’s medical treatments for NETS

NET Cancer Day in Minnesota 2018

Northwoods NETS is pleased to announce that Senator Mark Dayton has proclaimed Friday, November 10th, NET Cancer Awareness Day in the state of Minnesota. We thank Governor Dayton for his continued recognition of this unusual cancer. It is estimated that approximately 300 Minnesotans are diagnosed with each year with this poorly understood disease. NETS, also known as neuroendocrine tumors, are considered rare tumors that have either benign or malignant behaviors.

NCCN Guidelines for NET Patients

The National Comprehensive Cancer Network (NCCN) has recently released a new guideline book for patients  diagnosed with neuroendocrine tumors. With very readable language it discusses what neuroendocrine tumors are, how they are diagnosed, the various types of treatments that are available based on the location your neuroendocrine tumor was found, and treatment decisions. Also included in this guide is a dictionary to easily look up terms related to neuroendocrine tumors,

PRRT is finally approved in the U.S.

After years of randomized trials and nearly two decades of European data detailing peptide receptor radionuclide therapy, Advanced Accelerator Applications (AAA), a Novartis company, is pleased to announced that the FDA has approved the use of this therapy for patients with neuroendocrine tumors. The approval comes at a time when incidence of neuroendocrine cancers of the pancreas, lungs, and intestines are on the rise. About 7 in 100,000 people are